Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics, Inc. is trading at $7.45, up 5.23% on the session. The 50 day average sits at $18.24 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 33.1, which reads as weak, and MACD is bullish crossover. Volume is volume spike.

The nearest support is around $3.73 with resistance near $20.54, so that band frames the current range. Average daily movement is roughly $1.50, or about 20.1% of the share price, which is what any stop placement has to allow for. The overall health score of 32 out of 100 combines a trend score of 25, momentum of 50 and a risk score of 16.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.